NCT00555139

A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

Completed Phase 1 Last updated 4 August 2017

What this trial tests

Phase 1 trial testing GSK561679 tablet in Social Phobia in 35 participants. Completed in 10 January 2008.

Timeline

27 March 2007

Primary endpoint
10 January 2008

10 January 2008

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Primary purpose	treatment
Enrollment	35
Start date	27 March 2007
Primary completion	10 January 2008
Estimated completion	10 January 2008
Sites	8 locations across Spain

Drugs / interventions tested

• GSK561679 tablet
• GW876008 tablet
• alprazolam (alprazolam) — full drug profile →
• Placebo

Conditions studied

• Social Phobia — all drugs for Social Phobia →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 18 to 64, any sex, with Social Phobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare by neuroimaging techniques and public speaking, the way social anxiety patients respond after the administration of GW876008, GSK561679, alprazolam and placebo

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.
   Garakani A, Murrough JW, Freire RC, Thom RP, et al · · 2020 · cited 213× · PMID 33424664 · DOI 10.3389/fpsyt.2020.595584
2. Don't stress about CRF: assessing the translational failures of CRF<sub>1</sub>antagonists.
   Spierling SR, Zorrilla EP. · · 2017 · cited 131× · PMID 28265716 · DOI 10.1007/s00213-017-4556-2
3. Progress in corticotropin-releasing factor-1 antagonist development.
   Zorrilla EP, Koob GF. · · 2010 · cited 131× · PMID 20206287 · DOI 10.1016/j.drudis.2010.02.011
4. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism.
   Zorrilla EP, Heilig M, de Wit H, Shaham Y. · · 2013 · cited 83× · PMID 23294766 · DOI 10.1016/j.drugalcdep.2012.12.017
5. Use of functional imaging across clinical phases in CNS drug development.
   Borsook D, Becerra L, Fava M. · · 2013 · cited 46× · PMID 23860483 · DOI 10.1038/tp.2013.43
6. Update on corticotropin-releasing factor pharmacotherapy for psychiatric disorders: a revisionist view.
   Koob GF, Zorrilla EP. · · 2012 · cited 39× · PMID 22157874 · DOI 10.1038/npp.2011.213
7. The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.
   Grillon C, Hale E, Lieberman L, Davis A, et al · · 2015 · cited 36× · PMID 25430779 · DOI 10.1038/npp.2014.316